News from indivior A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Sep 30, 2020, 08:00 ET Indivior Calls for Widespread Commitment to Tackling Stigma in Patients with Opioid Use Disorder

Indivior PLC (LON:INDV) is calling for a public health dialogue aimed at breaking the stigmas associated with substance use disorders, including...


Sep 22, 2020, 08:30 ET Indivior Underscores Commitment to Putting Patients First during this Recovery Month

September is Recovery Month, a time to celebrate people in recovery and advocate for those who remain under-diagnosed, under-treated and...


Jun 30, 2020, 18:01 ET US Government Agreement With Former CEO

Indivior PLC (LON: INDV) notes that Shaun Thaxter, its former Chief Executive Officer, entered into an agreement with the U.S. Department of Justice...


Jun 24, 2020, 08:30 ET New Data from the RECOVER™ Study Reveal Two-Year Outcomes in People with Opioid Use Disorder Following Transition from Pivotal Phase 3 Clinical Trials to a Real-World Setting

Indivior PLC (LON: INDV) announces new data from the two-year analysis of the 24-month real-world observational study, RECOVER™ (Remission from...


Mar 23, 2020, 08:00 ET One-Year Outcomes of Real-World RECOVER™ Study Published in Journal of Addiction Medicine

Indivior PLC (LON: INDV) today announced the publication of one-year outcomes from a 24-month real-world observational study, RECOVER™ (Remission...


Nov 11, 2019, 12:43 ET Indivior Launches National Campaign Informing People of an Additional Treatment for Opioid Use Disorder (OUD) and to Let People with OUD Know That They Can "Keep Moving Towards Recovery"

Indivior PLC (LON: INDV) announces the launch of a new direct-to-consumer (DTC) advertising campaign, Keep Moving Towards Recovery, which aims to...


Oct 31, 2019, 07:25 ET Indivior 2019 Third Quarter and Nine Months Results Now Available; Conference Call With Leadership Today

Indivior PLC (LON: INDV) today announced that its Q3/YTD 2019 results press release and investor supplement are now available via the London Stock...


Jul 31, 2019, 02:45 ET Indivior First Half 2019 Results Now Available; Conference Call With Leadership Today

Indivior PLC (LON: INDV) today announced that its first half 2019 results press release and investor supplement are now available via the London...


Jun 17, 2019, 14:43 ET New Data from the RECOVER™ Study Reports on Abstinence, Drug Craving and Psychosocial Outcomes in People with Opioid Use Disorder following Transition from a Clinical Trial to the Real-World Setting

Indivior PLC (LON: INDV) today announced new data from a one-year analysis of the observational RECOVER™ (Remission from Chronic Opioid Use-Studying...


Apr 06, 2019, 08:36 ET Indivior Announces New Study Data in Patients with Moderate to Severe Opioid Use Disorder (OUD) at the 50th ASAM Annual Conference

Indivior PLC (LON: INDV) today announced data from two new studies: the first provides insights into dosing of once-monthly SUBLOCADE™ (buprenorphine ...


Apr 05, 2019, 08:36 ET Indivior's RECOVER™ Study Finds Three-quarters of Patients with Moderate to Severe Opioid Use Disorder Who Received 12 monthly Injections of SUBLOCADE™ (Buprenorphine Extended-Release) Injection were Abstinent from Illicit Opioids One Year Later

Indivior PLC (LON: INDV) today announced data from two studies evaluating efficacy and long-term safety of once-monthly SUBLOCADE™ (buprenorphine...


Mar 07, 2019, 10:30 ET The Journal of Addiction Medicine Publishes Patient-centered Outcomes from the Phase 3 Study of SUBLOCADE™ (Buprenorphine Extended-Release) Injection in Patients with Moderate to Severe Opioid Use Disorder (OUD)

Indivior PLC (LON: INDV) today announced the publication of patient-centered outcome endpoints (health status, physical and mental health, medication ...


Feb 19, 2019, 08:00 ET The Lancet Publishes Phase 3 Results Demonstrating Efficacy, Safety and Tolerability of SUBLOCADE™ (Buprenorphine Extended-Release) Injection for Subcutaneous Use (CIII) in Patients with Moderate to Severe Opioid Use Disorder (OUD)

Indivior PLC (LON: INDV) today announced that data from its pivotal phase 3 clinical trial evaluating the efficacy, safety and tolerability of...


Feb 14, 2019, 02:15 ET Indivior FY 2018 Financial Results

FY 2018 Adjusted Financial Results In-Line with Guidance. FY 2019 SUBLOCADE™ Guidance Introduced. Period to December 31st Q4 2018 $m Q4 2017 $m % ∆...


Dec 20, 2018, 09:00 ET Indivior Publishes Design and Patient Characteristics for Real-World Study of Life Changes in People Treated with SUBLOCADE™ (Buprenorphine Extended-Release) in Contemporary Clinical Trials

Indivior PLC (LON: INDV) today announced the publication of the study design and participant characteristics of the RECOVER (Remission from Chronic...


Oct 24, 2018, 14:32 ET Indivior Applauds Enactment of the SUPPORT for Patients and Communities Act of 2018

Indivior PLC (LON: INDV) ("Indivior" or the "Company") commends Congress and the Administration for passing and enacting H.R. 6, the SUPPORT for...


Jul 27, 2018, 19:44 ET FDA Approves PERSERIS™ (risperidone) for Extended-Release Injectable Suspension for the Treatment of Schizophrenia in Adults

Indivior PLC (LON: INDV) today announced that the U.S. Food and Drug Administration (FDA) has approved PERSERIS™, the first once-monthly subcutaneous ...


Apr 20, 2018, 09:00 ET Indivior Announces New Drug Submission to Health Canada for SUBLOCADE™ (Buprenorphine Extended-Release) Injection for the Treatment of Moderate to Severe Opioid Use Disorder

Indivior PLC (LON: INDV) today announced that it has filed a New Drug Submission (NDS) with Health Canada's Therapeutic Drugs Directorate for...


Apr 05, 2018, 08:00 ET Indivior Files Complaints Asserting New SUBOXONE® Film Patent Against ANDA-filers

Indivior PLC (LON: INDV) ("Indivior" or the "Company") today announced that its U.S. subsidiary, Indivior Inc., has filed patent lawsuits against Dr. ...


Nov 30, 2017, 19:52 ET FDA Approves SUBLOCADE™ (Buprenorphine Extended-Release), the First and Only Once-Monthly Injectable Buprenorphine Formulation to Treat Moderate to Severe Opioid Use Disorder

Indivior PLC (LON: INDV) today announced that the U.S. Food and Drug Administration (FDA) has approved SUBLOCADETM (buprenorphine extended- release)...